Clinical Usefulness of Monitoring Muscle Volume during Atezolizumab Plus Bevacizumab Therapy in Patients with Unresectable Hepatocellular Carcinoma

SIMPLE SUMMARY: Decrease of skeletal muscle mass index during atezolizumab plus bevacizumab therapy was significantly associated with poor progression-free survival in patients with unresectable hepatocellular carcinoma, while pretreatment sarcopenia was not a significant factor. These findings sugg...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsumoto, Hiroaki, Tsuchiya, Kaoru, Nakanishi, Hiroyuki, Hayakawa, Yuka, Yasui, Yutaka, Uchihara, Naoki, Suzuki, Keito, Tanaka, Yuki, Miyamoto, Haruka, Ishido, Shun, Yamada, Michiko, Keitoku, Taisei, Nobusawa, Tsubasa, Higuchi, Mayu, Takaura, Kenta, Tanaka, Shohei, Maeyashiki, Chiaki, Tamaki, Nobuharu, Takahashi, Yuka, Kurosaki, Masayuki, Asahina, Yasuhiro, Okamoto, Ryuichi, Izumi, Namiki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9322937/
https://www.ncbi.nlm.nih.gov/pubmed/35884610
http://dx.doi.org/10.3390/cancers14143551

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9322937/
https://www.ncbi.nlm.nih.gov/pubmed/35884610
http://dx.doi.org/10.3390/cancers14143551

Ejemplares similares